Overall verdict
Neutral
6.2/10
1-year performance
+40.17%
Score breakdown
Up 40.2% over 1 year, 100% of the 52-week range.
Strongest: Profitability 9.2/10. Weakest: Growth 2.7/10.
22 analysts, target -0.0% vs the price.
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
Sector
Health Care
Industry
Pharmaceuticals
Primary listing
Six
Switzerland
CEO
Dr. Thomas Schinecker
Founded
1896
Employees
112 774
Revenue / employee
556 195 CHF
Next earnings
January 28, 2027
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
406.50 CHF
52-week low
283.60 CHF
1-year performance
40.17%
Rising
Year-to-date performance
23.93%
Rising
Drawdown
0.00%
Near its high
Position in the 52-week range
100% of range
Range: 305.57 CHF - 361.34 CHF (2 methods agree)
The price implies growth of 6.08% per year; the company grows at -0.59%.
Gross margin 72.7%, net margin 20.3%, ROIC 21.8%, ROE 40.2%.
Net margin
20.25%
Exceptional
Sector 9.96%|S&P 13.40%
Gross margin
72.71%
Exceptional
Return on equity (ROE)
40.22%
Exceptional
Sector 6.73%|S&P 17.06%
Return on invested capital (ROIC)
21.83%
Exceptional
Free cash flow margin (FCF)
24.23%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.20x
High
Margin stability
2.8 pts
Steady
Revenue to net income
Growth
2.7/10Revenue down 1.2% over 1 year, 1.1% a year over 5, EPS -0.6% a year over 5.
Revenue (trailing 12 months)
60.9Md CHF
Revenue growth (1y)
-1.20%
Declining
Revenue growth (3y)
-2.79%
Declining
EPS growth (1y)
55.42%
Hyper-growth
EPS CAGR (5y)
-0.59%
Declining
EPS revisions (3 months)
0.82%
Revised up
Valuation
4.6/10P/E 26.5x, forward P/E 21.8x, EV/EBITDA 15.7x, PEG 0.86. The multiple sits in the 82th percentile of its own 5-year history.
P/E (TTM)
26.5x
Fair
Sector 27.8x|S&P 23.6x
Forward P/E
21.8x
Expensive
EV / EBITDA
15.7x
Fair
Sector 14.2x|S&P 15.5x
PEG
0.86
Growth unpriced
Sector 0.88|S&P 0.91
Fair value (reverse DCF)
333.45 CHF
Overvalued
P/E vs its own 5-year history
among the 18% highest valuations
At its historical high
Market cap
321Md CHF
Financial strength
8.2/10Cash covers 30.6% of the debt, net debt/EBITDA 0.8x.
Net debt / EBITDA
0.8x
Solid
Gearing (net debt / equity)
60.11%
Tight
Cash
9.5Md CHF
Cash / market cap
2.98%
Stretched
Cash / total debt
30.61%
Solid
Interest coverage
16.3x
Very solid
Net debt
21.6Md CHF
Equity
36.0Md CHF
Closed daily candles, 2 years
Last close on November 11, 2026: 401.90 CHF
- MM20393.71
- MM50371.12
- MM200345.91
- RSI 1465.9
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.60%
200-day average slope, 3 months
+5.52%
50-day average slope, 1 month
+3.38%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.18 % per day
Volatility change
-20.32%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 18.60 (11) | 20.52 (19) | 63 507 (13) | 25 366 (16) | 14 992 (12) |
| 2027 | 20.61 (11) | 22.06 (20) | 66 294 (17) | 27 452 (16) | 16 593 (12) |
Amounts in millions of CHF, EPS in CHF per share. In brackets, the number of analysts. Consensus as of November 9, 2026.
Same sub-industry: 503 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AZN | 7.1 | 7.0 | 286Md USD | 26.7x | 17.7 % | 7.1 % | 14.4 % | 1.2x | 3.6 % | 3.7 % | ||
| 2 | BMY | 6.6 | 6.9 | 129Md USD | 13.9x | 18.5 % | 7.0 % | 14.0 % | 1.9x | 7.2 % | 32.5 % | ||
| 3 | NOVO B | 6.2 | 7.7 | 178Md USD | 10.7x | 33.9 % | 5.6 % | 38.1 % | 0.7x | 6.0 % | -8.5 % | ||
| 4 | ROP | 6.2 | 6.4 | 385Md USD | 26.5x | 20.3 % | -1.2 % | 21.8 % | 0.8x | 4.6 % | 40.2 % | ||
| 5 | NOVN | 6.1 | 6.5 | 295Md USD | 32.0x | 18.0 % | 6.0 % | 13.5 % | 1.0x | 5.0 % | 29.2 % | ||
| 6 | LLY | 6.0 | 5.1 | 1.4T USD | 47.2x | 31.9 % | 38.6 % | 36.3 % | 1.2x | 1.5 % | 48.7 % | ||
| 7 | JNJ | 5.6 | 5.2 | 675Md USD | 42.5x | 16.2 % | 5.9 % | 13.6 % | 0.9x | 3.1 % | 48.1 % | ||
| 8 | MRK | 5.4 | 3.6 | 363Md USD | 150.3x | 3.6 % | 5.5 % | 2.6 % | 1.2x | 4.1 % | 68.5 % | ||
| 9 | PFE | 5.2 | 4.6 | 168Md USD | 42.1x | 6.3 % | -0.4 % | 2.7 % | 2.3x | 7.0 % | 20.3 % |
